Literature DB >> 15271011

High incidence of appropriate and inappropriate ICD therapies in children and adolescents with implantable cardioverter defibrillator.

Thomas Korte1, Harald Köditz, Michael Niehaus, Thomas Paul, Jürgen Tebbenjohanns.   

Abstract

Appropriate and inappropriate therapies of implantable cardioverter defibrillators have a major impact on morbidity and quality of life in ICD recipients, but have not been systematically studied in children and young adults during long-term follow-up. ICD implantation was performed in 20 patients at the mean age of 16 +/- 6 years, 11 of which had prior surgical repair of a congenital heart defect, 9 patients had other cardiac diseases. Implant indications were aborted sudden cardiac death in six patients, recurrent ventricular tachycardia in 9 patient, and syncope in 5 patients. Epicardial implantation was performed in 6 and transvenous implantation in 14 patients. Incidence, reasons and predictors (age, gender, repaired congenital heart disease, history of supraventricular tachycardia, and epicardial electrode system) of appropriate and inappropriate ICD therapies were analyzed during a mean follow-up period of 51 +/- 31 months range 18-132 months. There were a total 239 ICD therapies in 17 patients (85%) with a therapy rate of 2.8 per patient-years of follow-up. 127 (53%) ICD therapies in 15 (75%) patients were catagorized as appropriate and 112 (47%) therapies in 10 (50%) patients as inappropriate, with a rate of 1.5 appropriate and 1.3 inappropriate ICD therapies per patient-years of follow-up. Time to first appropriate therapy was 16 +/- 18 months. Appropriate therapies were caused by ventricular fibrillation in 29 and ventricular tachycardia in 98 episodes. Termination was successful by antitachycardia pacing in 4 (3%) and by shock therapy in 123 episodes (97%). Time to first inappropriate therapy was 16 +/- 17 months. Inappropriate therapies were caused by supraventricular tachycardia in 77 (69%), T wave oversensing in 19 (17%), and electrode defect in 16 episodes (14%). It caused shocks in 87 (78%) and only antitachycardia pacing in 25 episodes (22%). No clinical variable could be identified as predictor of either appropriate or inappropriate ICD therapies. There is a high rate of ICD therapies in young ICD recipients, the majority of which occur during early follow-up. The rate of inappropriate therapies is as high as 47% and is caused by supraventricular tachycardia and electrode complications in the majority of cases. Prospective trials are required to establish preventative strategies of ICD therapies in this young patient population.

Entities:  

Mesh:

Year:  2004        PMID: 15271011     DOI: 10.1111/j.1540-8159.2004.00560.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  21 in total

1.  Outcomes after implantable cardioverter-defibrillator treatment in children with hypertrophic cardiomyopathy.

Authors:  Juan Pablo Kaski; María Teresa Tomé Esteban; Martin Lowe; Simon Sporton; Philip Rees; John E Deanfield; William J McKenna; Perry M Elliott
Journal:  Heart       Date:  2006-08-29       Impact factor: 5.994

2.  Primary prevention with the ICD in clinical practice: not as straightforward as the guidelines suggest?

Authors:  F A L E Bracke; L R C Dekker; P H van der Voort; A Meijer
Journal:  Neth Heart J       Date:  2009-03       Impact factor: 2.380

Review 3.  Implantable cardioverter-defibrillators in adults with congenital heart disease: a systematic review and meta-analysis.

Authors:  Jim T Vehmeijer; Tom F Brouwer; Jacqueline Limpens; Reinoud E Knops; Berto J Bouma; Barbara J M Mulder; Joris R de Groot
Journal:  Eur Heart J       Date:  2016-02-11       Impact factor: 29.983

Review 4.  Surgical techniques for implanting implantable cardioverter defibrillators in children and infants.

Authors:  Shoji Suzuki; Shinya Motohashi; Masahiko Matsumoto
Journal:  Surg Today       Date:  2013-10-24       Impact factor: 2.549

5.  Current practices in the monitoring of cardiac rhythm devices in pediatrics and congenital heart disease.

Authors:  Stacey L Boyer; Michael J Silka; Yaniv Bar-Cohen
Journal:  Pediatr Cardiol       Date:  2014-12-20       Impact factor: 1.655

6.  Multicenter study of the effectiveness of implantable cardioverter defibrillators in children and young adults with heart disease.

Authors:  Nicholas H Von Bergen; Dianne L Atkins; Macdonald Dick; David J Bradley; Susan P Etheridge; Elizabeth V Saarel; Peter S Fischbach; Seshadri Balaji; Narayanswami Sreeram; William N Evans; Ian H Law
Journal:  Pediatr Cardiol       Date:  2011-01-06       Impact factor: 1.655

7.  An unusual resolution of T-wave oversensing in an implantable cardioverter defibrillator in a child with long QT syndrome.

Authors:  Mitchell I Cohen; Petros V Anagnostopoulos; Andrew Papez
Journal:  J Interv Card Electrophysiol       Date:  2009-01-16       Impact factor: 1.900

8.  Optimal Programming of ICDs for Prevention of Appropriate and Inappropriate Shocks.

Authors:  Ronald Lo; Amin Al-Ahmad; Henry Hsia; Paul C Zei; Paul J Wang
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-09

9.  Update on the use and outcomes of implantable cardioverter defibrillators in pediatric patients.

Authors:  Christian J Turner; Elizabeth A Stephenson
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-10

10.  Determinants of implantable defibrillator discharges in high-risk patients with hypertrophic cardiomyopathy.

Authors:  Anna Woo; Daniel Monakier; Louise Harris; Ann Hill; Prasad Shah; E Douglas Wigle; Harry Rakowski; Evelyn Rozenblyum; Douglas A Cameron
Journal:  Heart       Date:  2007-09       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.